biosimilars

The NHS Drug Reimbursement Policy in the UK is a critical framework that ensures patients receive access to effective and affordable medicines while maintaining the financial sustainability of the healthcare system. This policy evaluates drugs for reimbursement based on cost-effectiveness, clinical efficacy, and societal value, often guided by assessments from the National Institute for Health and Care Excellence (NICE). It encompasses a range of treatments, including branded drugs, generics, and biosimilars, aiming to balance innovation with equitable access. Despite its strengths, the policy faces challenges such as rising drug costs, regional disparities, and the complexities of approving high-cost innovative therapies. Addressing these challenges is essential for delivering high-quality care to patients across the UK.